AIDS vaccine advisory committee
Executive Summary
An ongoing Phase III study of Aventis-Pasteur's ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX will be discussed at FDA's Vaccines & Related Biologics Advisory Committee's Sept. 23 meeting. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 9 a.m. The committee will be closed from 11 a.m. to 12:15 p.m. to discuss trade secret/confidential information [Editor's Note: To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...